Aesthetics Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Log In

Management of Diabetic Retinopathy

By: Nathan Steinle, MD

Multimedia Credits: .5

Changing Approach to Diabetic Retinopathy Management

In 2015, there were 415 million people worldwide living with diabetes. Of those, 145 million had diabetic retinopathy (DR), and roughly one-third of those had severe vision loss, according to the International Diabetes Federation. By 2040, experts estimate 224 million people will have some form of DR and 70 million will have vision-threatening DR.

Study results now indicate that early diagnosis and referral to a retina specialist for treatment of DR can help slow the disease progression. Patients must be educated about the importance of regular examinations because microvascular damage is often present even in patients without overt disease.

This activity will focus on the importance of early and timely referral of patients with DR to retina specialists and understanding how DR may affect patients with cataracts.

Expiration Date: Thursday, November 03, 2022
Release Date: March 2020



Step 1 of 3

  • AgreeNeutralDisagree
    Recognize the importance of early diagnosis and treatment of age-related macular degeneration (AMD) and diabetic macular edema (DME).
    Assess the response of anti-vascular endothelial growth factor (VEGF) intravitreal injections and define “suboptimal responders.”
    Understand the most recent monotherapy and combination therapy clinical study evidence using available therapies for AMD, DME, and retinal vein occlusion (RVO).
    Discuss the outcomes of pivotal studies in AMD, DME, and RVO and how study results may differ from real-world dosing methods.
    Develop individualized treatment plans for patients with retina disorders that use a combination of imaging, treat and extend, or treat and observe.
    Discuss the ocular and systemic effects of anti-VEGF therapies and how to educate patients on appropriate expectations.